<?xml version='1.0' encoding='utf-8'?>
<document id="29749254"><sentence text="UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions." /><sentence text="Coproporphyrins (CP-I and CP-III) have been identified as possible biomarkers to predict human hepatic organic anion-transporting polypeptides-mediated-drug-interactions for a new drug entering clinical development"><entity charOffset="0-15" id="DDI-PubMed.29749254.s2.e0" text="Coproporphyrins" /></sentence><sentence text="" /><sentence text="The method is applicable to quantify plasma CP-I and CP-III within 0" /><sentence text="078-15" /><sentence text="0Â nM" /><sentence text=" The results identify and address a number of challenges encountered with porphyrin assays such as photodegradation and interferences"><entity charOffset="74-83" id="DDI-PubMed.29749254.s7.e0" text="porphyrin" /></sentence><sentence text=" To overcome interferences from ubiquitous porphyrins, a surrogate matrix was used to prepare calibration standards" /><sentence text=" Quality controls were prepared in plasma and surrogate matrix to ensure parallelism between surrogate matrix and plasma" /><sentence text="" /><sentence text="A robust UHPLC-MS/MS assay was developed and validated for CP-I and CP-III in plasma, and is currently applied to clinical studies to confirm suitability of Coproporphyrins as a potential substitute for drug-drug interaction study"><entity charOffset="157-172" id="DDI-PubMed.29749254.s11.e0" text="Coproporphyrins" /></sentence><sentence text="" /></document>